The bacterial superantigen and superantigen-like proteins

Immunological Reviews

Volumn 225, Issue 1, 2008, Pages 226-243

  Fraser, John D ^a   Proft, Thomas ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Enterotoxin; MHC; Staphylococcus; Superantigen; TCR; Toxic shock

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; CYTOKINE; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; P SELECTIN GLYCOPROTEIN LIGAND 1; PROTEIN INHIBITOR; SAG PROTEIN; SSL11 TOXIN; SSL5 TOXIN; STAPHYLOCOCCAL ENTEROTOXIN LIKE TOXIN; STAPHYLOCOCCUS ENTEROTOXIN; STAPHYLOCOCCUS ENTEROTOXIN A; STAPHYLOCOCCUS ENTEROTOXIN B; STAPHYLOCOCCUS ENTEROTOXIN C; STAPHYLOCOCCUS ENTEROTOXIN D; STAPHYLOCOCCUS ENTEROTOXIN E; STAPHYLOCOCCUS ENTEROTOXIN G; STAPHYLOCOCCUS ENTEROTOXIN H; STAPHYLOCOCCUS ENTEROTOXIN I; STAPHYLOCOCCUS ENTEROTOXIN J; SUPERANTIGEN; SUPERANTIGEN LIKE PROTEIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BLOCKING AGENT; TOXIC SHOCK SYNDROME TOXIN 1; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ADAPTIVE IMMUNITY; ALLERGIC RHINITIS; ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL SKIN DISEASE; BACTERIAL VIRULENCE; CARBOXY TERMINAL SEQUENCE; CLINICAL FEATURE; CYTOKINE PRODUCTION; DRUG MEGADOSE; EPIDEMIC; GENE EXPRESSION REGULATION; HUMAN; IMMUNOTHERAPY; INFECTION SENSITIVITY; MENSTRUATION; MYCOPLASMA ARTHRITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; SCARLET FEVER; SEQUENCE HOMOLOGY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCAL TOXIC SHOCK SYNDROME; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS EQUI; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; STRUCTURE ANALYSIS; T LYMPHOCYTE ACTIVATION; TOXIC SHOCK SYNDROME; TOXIN ANALYSIS; YERSINIA PSEUDOTUBERCULOSIS;

ANTIGENS, BACTERIAL; ENTEROTOXINS; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANTIGEN, T-CELL; SEQUENCE ALIGNMENT; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SUPERANTIGENS; T-LYMPHOCYTES;

EID: 52049123299     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00681.x     Document Type: Review

References (162)

1. Jupin C, Anderson S, Damais C, Alouf JE, Parant M. Toxic shock syndrome toxin as an inducer of human tumor necrosis factors and g-interferon. J Exp Med 1988 167 : 752 761.
2. White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P. The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell 1989 56 : 27 35.
3. Bergdoll MS. Enterotoxins. In : Easom CSF, Adlam C, eds. Staphyloccoi and Staphylococcal Infections. New York : Academic Press, 1983 : 559 598.
4. Bergdoll MS, Crass BA, Reiser RF, Robbins RN, Davis JP. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet 1981 1 : 1017 1021.
5. Dick G, Dick G. Landmark article Jan 26, 1924: the etiology of scarlet fever. By George F. Dick and Gladys Henry Dick. JAMA 1983 250 : 3096.
6. Kim Y, Watson D. Apurified group A streptococcal pyrogenic exotoxin. Physiochemical and biological properties, including the enhancement of susceptibility to endotoxin lethal shock. J Exp Med 1970 131 : 611 622.
7. Willoughby R, Greenberg RN. The toxic shock syndrome and streptococcal pyrogenic exotoxins. Ann Int Med 1983 98 : 559.
8. Stevens DL, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989 321 : 1 7.
9. Peavy D, Alder WH, Smith RT. The mitogenic effects of endotoxin and Staphylococcal enterotoxin B on mouse spleen cells and human peripheral lymphocytes. J Immunol 1970 105 : 1453 1458.
10. Fraser JD. High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR. Nature 1989 339 : 221 223.
11. Fischer H, Dohlsten M, Lindvall M, Sjogren HO, Carlsson R. Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines. J Immunol 1989 142 : 3151 3157.
12. Scholl P, Diez A, Mourad W, Parsonnet J, Geha RS, Chatila T. Toxic shock syndrome toxin 1 binds to major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1989 86 : 4210 4214.
13. Kappler J, et al. Vß-specific stimulation of human Tcells by Staphylococcal toxins. Science 1989 244 : 811 813.
14. Dellabona P, Peccoud J, Kappler J, Marrack P, Benoist C, Mathis D. Superantigens interact with MHC class II molecules outside of the antigen groove. Cell 1990 62 : 1115 1121.
15. Buxser S, Vroegop S. Staphylococcal enterotoxin B stimulation of BALB/c lymphocyte mitogenesis and potential relationship to the Mls response. J Immunogenet 1988 15 : 153 159.
16. Janeway CJ, Fischer LK, Hammerling U. The Mls locus: new clues to a lingering mystery (news). Immunol Today 1988 9 : 125 126.
17. Janeway CJ, et al. T-cell responses to Mls and to bacterial proteins that mimic its behavior. Immunol Rev 1989 107 : 61 68.
18. Woodland DL, Happ MP, Gollob KJ, Palmer E. An endogenous retrovirus mediating deletion of alpha-beta T cells? Nature 1991 349 : 529 530.
19. Acha-Orbea H, et al. Clonal deletion of Vß 14-bearing T cells in mice transgenic for mammary tumour virus. Nature 1991 350 : 207 211.
20. Marrack P, Kushnir E, Kappler J. A maternally inherited superantigen encoded by a mammary tumour virus (see comments). Nature 1991 349 : 524 526.
21. Held W, Waanders GA, Shakhov AN, Scarpellino L, Acha-Orbea H, MacDonald HR. Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission. Cell 1993 74 : 529 540.
22. Chu FS, Thadhani K, Schantz EJ, Bergdoll MS. Purification and characterization of staphylococcal enterotoxin A. Biochemistry 1966 5 : 3281 3289.
23. Thomas D, Chou S, Dauwalder O, Lina G. Diversity in Staphylococcus aureus enterotoxins. Chem Immunol Allergy 2007 93 : 24 41.
24. Thomas DY, et al. Staphylococcal enterotoxin-like toxins U2 and V, two new staphylococcal superantigens arising from recombination within the enterotoxin gene cluster. Infect Immun 2006 74 : 4724 4734.
25. Lina G, Bohach GA, Nair SP, Hiramatsu K, Jouvin-Marche E, Mariuzza R. Standard nomenclature for the superantigens expressed by Staphylococcus. J Infect Dis 2004 189 : 2334 2336.
26. Hudson KR, Robinson H, Fraser JD. Two adjacent residues in staphylococcal enterotoxins A and E determine T cell receptor V beta specificity. J Exp Med 1993 177 : 175 184.
27. Baba T, et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002 359 : 1819 1827.
28. Ruzin A, Lindsay J, Novick RP. Molecular genetics of SaPI1 - a mobile pathogenicity island in Staphylococcus aureus. Mol Microbiol 2001 41 : 365 377.
29. Watson D. Host-parasite factors in group A streptococcal infections. Pyrogenic and other effects of immunologic distinct exotoxins related to scarlet fever toxins. J Exp Med 1960 111 : 255 284.
30. Hooker S, Follensby E. Studies on scarlet fever. II. Different toxins produced by hemolytic streptococci of scarlatinal origin. J Immunol 1934 27 : 177 193.
31. Stock AH, Lynn RJ. Extracellular esterases of streptococci and the distribution of specific antibodies in human sera of various age groups. J Immunol 1969 102 : 859 869.
32. Kansal RG, Nizet V, Jeng A, Chuang WJ, Kotb M. Selective modulation of superantigen-induced responses by streptococcal cysteine protease. J Infect Dis 2003 187 : 398 407.
33. Nooh MM, et al. Streptococcal mitogenic exotoxin, SmeZ, is the most susceptible M1T1 streptococcal superantigen to degradation by the streptococcal cysteine protease, SpeB. J Biol Chem 2006 281 : 35281 35288.
34. Weeks CR, Ferretti JJ. Nucleotide sequence of the type A Streptococcal exotoxin (Erthrogenic toxin) gene from Streptococcus pyrogenes Bacteriophage T12. Infect Immun 1986 52 : 144 150.
35. Beres SB, et al. Genome sequence of a serotype M3 strain of group A Streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone emergence. Proc Natl Acad Sci USA 2002 99 : 10078 10083.
36. Ikebe T, et al. Dissemination of the phage-associated novel superantigen gene speL in recent invasive and noninvasive Streptococcus pyogenes M3/T3 isolates in Japan. Infect Immun 2002 70 : 3227 3233.
37. Proft T, Webb PD, Handley V, Fraser JD. Two novel superantigens found in both group A and group C Streptococcus. Infect Immun 2003 71 : 1361 1369.
38. Smoot LM, et al. Characterization of two novel pyrogenic toxin superantigens made by an acute rheumatic fever clone of Streptococcus pyogenes associated with multiple disease outbreaks. Infect Immun 2002 70 : 7095 7104.
39. Proft T, Moffatt SL, Weller KD, Paterson A, Martin D, Fraser JD. The streptococcal superantigen SMEZ exhibits wide allelic variation, mosaic structure, and significant antigenic variation. J Exp Med 2000 191 : 1765 1776.
40. Proft T, Moffatt SL, Berkahn CJ, Fraser JD. Identification and characterization of novel superantigens from Streptococcus pyogenes. J Exp Med 1999 189 : 89 102.
41. Unnikrishnan M, et al. The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent of Streptococcus pyogenes. J Immunol 2002 169 : 2561 2569.
42. Proft T, Sriskandan S, Yang L, Fraser JD. Superantigens and streptococcal toxic shock syndrome. Emerg Infect Dis 2003 9 : 1211 1218.
43. Artiushin SC, Timoney JF, Sheoran AS, Muthupalani SK. Characterization and immunogenicity of pyrogenic mitogens SePE-H and SePE-I of Streptococcus equi. Microb Pathog 2002 32 : 71 85.
44. Miyoshi-Akiyama T, et al. Streptococcus dysgalactiae-derived mitogen (SDM), a novel bacterial superantigen: characterization of its biological activity and predicted tertiary structure. Mol Microbiol 2003 47 : 1589 1599.
45. Sachse S, et al. Superantigen-like gene(s) in human pathogenic Streptococcus dysgalactiae, subsp equisimilis: genomic localisation of the gene encoding streptococcal pyrogenic exotoxin G [speG(dys)]. FEMS Immunol Med Microbiol 2002 34 : 159 167.
46. Williams RJ, et al. Identification of a novel gene cluster encoding staphylococcal exotoxin-like proteins: characterization of the prototypic gene and its protein product, SET1. Infect Immun 2000 68 : 4407 4415.
47. Kuroda M, et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 2001 357 : 1225 1240.
48. Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD. The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. J Immunol 2005 174 : 2926 2933.
49. Wines BD, Willoughby N, Fraser JD, Hogarth PM. A competitive mechanism for staphylococcal toxin SSL7 inhibiting the leukocyte IgA receptor, Fc alphaRI, is revealed by SSL7 binding at the C alpha2/C alpha3 interface of IgA. J Biol Chem 2006 281 : 1389 1393.
50. Ramsland PA, et al. Structural basis for evasion of IgA immunity by Staphylococcus aureus revealed in the complex of SSL7 with Fc of human IgA1. Proc Natl Acad Sci USA 2007 104 : 15051 15056.
51. Baker HM, Basu I, Chung MC, Caradoc-Davies T, Fraser JD, Baker EN. Crystal structures of the staphylococcal toxin SSL5 in complex with sialyl Lewis X reveal a conserved binding site that shares common features with viral and bacterial sialic acid binding proteins. J Mol Biol 2007 374 : 1298 1308.
52. Chung MC, Wines BD, Baker H, Langley RJ, Baker EN, Fraser JD. The crystal structure of staphylococcal superantigen-like protein 11 in complex with sialyl Lewis X reveals the mechanism for cell binding and immune inhibition. Mol Microbiol 2007 66 : 1342 1355.
53. Bestebroer J, et al. Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood 2007 109 : 2936 2943.
54. Cole BC, Tuller JW, Sullivan GJ. Stimulation of mouse lymphocytes by a mitogen derived from Mycoplasma arthritidis. VI. Detection of a non-MHC gene(s) in the E alpha-bearing RIIIS mouse strain that is associated with a specific lack of T cell responses to the M. arthritidis soluble mitogen. J Immunol 1987 139 : 927 935.
55. Alvarez-Ossorio L, Johannsen M, Alvarez-Ossorio R, Nicklas W, Kirchner H, Rink L. Cytokine induction by Mycoplasma arthritidis-derived superantigen (MAS), but not by TSST-1 or SEC-3, is correlated to certain HLA-DR types. Scand J Immunol 1998 47 : 43 47.
56. Cole BC, Sawitzke AD, Ahmed EA, Atkin CL, David CS. Allelic polymorphisms at the H-2A and HLA-DQ loci influence the response of murine lymphocytes to the Mycoplasma arthritidis superantigen MAM. Infect Immun 1997 65 : 4190 4198.
57. Mu HH, Humphreys J, Chan FV, Cole BC. TLR2 and TLR4 differentially regulate B7-1 resulting in distinct cytokine responses to the mycoplasma superantigen MAM as well as to disease induced by Mycoplasma arthritidis. Cell Microbiol 2006 8 : 414 426.
58. Mu HH, Pennock ND, Humphreys J, Kirschning CJ, Cole BC. Engagement of Toll-like receptors by mycoplasmal superantigen: downregulation of TLR2 by MAM/TLR4 interaction. Cell Microbiol 2005 7 : 789 797.
59. Diedershagen M, Overbeck S, Arlt S, Plumakers B, Lintges M, Rink L. Mycoplasma arthritidis-derived superantigen (MAM) displays DNase activity. FEMS Immunol Med Microbiol 2007 49 : 266 271.
60. Wang L, et al. Crystal structure of a complete ternary complex of TCR, superantigen and peptide-MHC. Nat Struct Mol Biol 2007 14 : 169 171.
61. Zhao Y, Li Z, Drozd SJ, Guo Y, Mourad W, Li H. Crystal structure of Mycoplasma arthritidis mitogen complexed with HLA-DR1 reveals a novel superantigen fold and a dimerized superantigen-MHC complex. Structure 2004 12 : 277 288.
62. Yoshino K, et al. Purification and characterization of a novel superantigen produced by a clinical isolate of Yersinia pseudotuberculosis. FEBS Letters 1994 356 : 141 144.
63. Abe J, Takeda T. Characterization of a superantigen produced by Yersinia pseudotuberculosis. Prep Biochem Biotechnol 1997 27 : 173 208.
64. Donadini R, Liew CW, Kwan AH, Mackay JP, Fields BA. Crystal and solution structures of a superantigen from Yersinia pseudotuberculosis reveal a jelly-roll fold. Structure 2004 12 : 145 156.
65. Lindsay JA, Ruzin A, Ross HF, Kurepina N, Novick RP. The gene for toxic shock toxin is carried by a family of mobile pathogenicity islands in Staphylococcus aureus. Mol Microbiol 1998 29 : 527 543.
66. Subedi A, Ubeda C, Adhikari RP, Penades JR, Novick RP. Sequence analysis reveals genetic exchanges and intraspecific spread of SaPI2, a pathogenicity island involved in menstrual toxic shock. Microbiology 2007 153 : 3235 3245.
67. Fitzgerald JR, et al. Genome diversification in Staphylococcus aureus: molecular evolution of a highly variable chromosomal region encoding the staphylococcal exotoxin-like family of proteins. Infect Immun 2003 71 : 2827 2838.
68. Ferretti JJ, et al. Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc Natl Acad Sci USA 2001 98 : 4658 4663.
69. Zabriskie JB. The role of temperate bacteriophage in the production of erythrogenic toxin by group a streptococci. J Exp Med 1964 119 : 761 780.
70. Banks DJ, et al. Progress toward characterization of the group A Streptococcus metagenome: complete genome sequence of a macrolide-resistant serotype M6 strain. J Infect Dis 2004 190 : 727 738.
71. Vojtek I, Pirzada ZA, Henriques-Normark B, Mastny M, Janapatla RP, Charpentier E. Lysogenic transfer of group A Streptococcus superantigen gene among Streptococci. J Infect Dis 2008 197 : 225 234.
72. Kazmi SU, et al. Reciprocal, temporal expression of SpeA and SpeB by invasive M1T1 group a streptococcal isolates in vivo. Infect Immun 2001 69 : 4988 4995.
73. Broudy TB, Pancholi V, Fischetti VA. Induction of lysogenic bacteriophage and phage-associated toxin from group a streptococci during coculture with human pharyngeal cells. Infect Immun 2001 69 : 1440 1443.
74. Graham MR, et al. Group A Streptococcus transcriptome dynamics during growth in human blood reveals bacterial adaptive and survival strategies. Am J Pathol 2005 166 : 455 465.
75. Virtaneva K, et al. Longitudinal analysis of the group A Streptococcus transcriptome in experimental pharyngitis in cynomolgus macaques. Proc Natl Acad Sci USA 2005 102 : 9014 9019.
76. Walker MJ, et al. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med 2007 13 : 981 985.
77. Novick RP. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 2003 48 : 1429 1449.
78. Torres VJ, et al. A Staphylococcus aureus regulatory system that responds to host heme and modulates virulence. Cell Host Microbe 2007 1 : 109 119.
79. Vojtov N, Ross HF, Novick RP. Global repression of exotoxin synthesis by staphylococcal superantigens. Proc Natl Acad Sci USA 2002 99 : 10102 10107.
80. Schad EM, et al. Crystal structure of the superantigen staphylococcal enterotoxin type A. EMBO J 1995 14 : 3292 3301.
81. Swaminathan S, Furey W, Pletcher J, Sax M. Crystal structure of staphylococcal enterotoxin B, a superantigen. Nature 1992 359 : 801 806.
82. Papageorgiou AC, Acharya KR, Shapiro R, Passalacqua EF, Brehm RD, Tranter HS. Crystal structure of the superantigen enterotoxin C2 from Staphylococcus aureus reveals a zinc-binding site. Structure 1995 3 : 769 779.
83. Fields BA, et al. Crystal structure of a T-cell receptor beta-chain complexed with a superantigen. Nature 1996 384 : 188 192.
84. Sundstrom M, Abrahmsen L, Antonsson P, Mehindate K, Mourad W, Dohlsten M. The crystal structure of staphylococcal enterotoxin type D reveals Zn2+-mediated homodimerization. EMBO J 1996 15 : 6832 6840.
85. Fernandez MM, et al. Superantigen natural affinity maturation revealed by the crystal structure of staphylococcal enterotoxin G and its binding to T-cell receptor Vbeta8.2. Proteins 2007 68 : 389 402.
86. Hakansson M, et al. The crystal structure of staphylococcal enterotoxin H: implications for binding properties to MHC class II and TCR molecules. J Mol Biol 2000 302 : 527 537.
87. Fernandez MM, Guan R, Swaminathan CP, Malchiodi EL, Mariuzza RA. Crystal structure of staphylococcal enterotoxin I (SEI) in complex with a human major histocompatibility complex class II molecule. J Biol Chem 2006 281 : 25356 25364.
88. Gunther S, et al. A novel loop domain in superantigens extends their T cell receptor recognition site. J Mol Biol 2007 371 : 210 221.
89. Acharya KR, et al. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Nature 1994 367 : 94 97.
90. Papageorgiou AC, et al. Structural basis for the recognition of superantigen streptococcal pyrogenic exotoxin A (SpeA1) by MHC class II molecules and T-cell receptors. EMBO J 1999 18 : 9 21.
91. Roussel A, Anderson BF, Baker HM, Fraser JD, Baker EN. Crystal structure of the streptococcal superantigen SPE-C: dimerization and zinc binding suggest a novel mode of interaction with MHC class II molecules. Nat Struct Biol 1997 4 : 635 643.
92. Arcus VL, Proft T, Sigrell JA, Baker HM, Fraser JD, Baker EN. Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from Streptococcus pyogenes. J Mol Biol 2000 299 : 157 168.
93. Brouillard JN, et al. Crystal structure of the streptococcal superantigen SpeI and functional role of a novel loop domain in T cell activation by group V superantigens. J Mol Biol 2007 367 : 925 934.
94. Baker HM, Proft T, Webb PD, Arcus VL, Fraser JD, Baker EN. Crystallographic and mutational data show that the streptococcal pyrogenic exotoxin J can use a common binding surface for T-cell receptor binding and dimerization. J Biol Chem 2004 279 : 38571 38576.
95. Saarinen S, Kato H, Uchiyama T, Miyoshi-Akiyama T, Papageorgiou AC. Crystal structure of Streptococcus dysgalactiae-derived mitogen reveals a zinc-binding site and alterations in TCR binding. J Mol Biol 2007 373 : 1089 1097.
96. Murzin AG. OB(oligonucleotide/oligosaccharide binding)-fold: common structural and functional solution for non-homologous sequences. EMBO J 1993 12 : 861 867.
97. Zhang C, Kim SH. The anatomy of protein beta-sheet topology. J Mol Biol 2000 299 : 1075 1089.
98. Al-Shangiti AM, Naylor CE, Nair SP, Briggs DC, Henderson B, Chain BM. Structural relationships and cellular tropism of staphylococcal superantigen-like proteins. Infect Immun 2004 72 : 4261 4270.
99. Arcus VL, Langley R, Proft T, Fraser JD, Baker EN. The Three-dimensional structure of a superantigen-like protein, SET3, from a pathogenicity island of the Staphylococcus aureus genome. J Biol Chem 2002 277 : 32274 32281.
100. Pless DD, Ruthel G, Reinke EK, Ulrich RG, Bavari S. Persistence of zinc-binding bacterial superantigens at the surface of antigen-presenting cells contributes to the extreme potency of these superantigens as T-cell activators. Infect Immun 2005 73 : 5358 5366.
101. Sundberg EJ, Deng L, Mariuzza RA. TCR recognition of peptide/MHC class II complexes and superantigens. Semin Immunol 2007 19 : 262 271.
102. Nooh MM, El-Gengehi N, Kansal R, David CS, Kotb M. HLA transgenic mice provide evidence for a direct and dominant role of HLA class II variation in modulating the severity of streptococcal sepsis. J Immunol 2007 178 : 3076 3083.
103. Sriskandan S, et al. Enhanced susceptibility to superantigen-associated streptococcal sepsis in human leukocyte antigen-DQ transgenic mice. J Infect Dis 2001 184 : 166 173.
104. Jardetzky TS, et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994 368 : 711 718.
105. Kim J, Urban RG, Strominger JL, Wiley DC. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. Science 1994 266 : 1870 1874.
106. Li Y, et al. Crystal structure of a superantigen bound to the high-affinity, zinc-dependent site on MHC class II. Immunity 2001 14 : 93 104.
107. Petersson K, et al. Crystal structure of a superantigen bound to MHC class II displays zinc and peptide dependence. EMBO J 2001 20 : 3306 3312.
108. Tiedemann RE, Urban RJ, Strominger JL, Fraser JD. Isolation of HLA-DR1.(staphylococcal enterotoxin A)2 trimers in solution. Proc Natl Acad Sci USA 1995 92 : 12156 12159.
109. Tiedemann RE, Fraser JD. Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation. J Immunol 1996 157 : 3958 3966.
110. Li H, et al. Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. Immunity 1998 9 : 807 816.
111. Kotb M, et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002 8 : 1398 1404.
112. Sundberg EJ, Li Y, Mariuzza RA. So many ways of getting in the way: diversity in the molecular architecture of superantigen-dependent T-cell signaling complexes. Curr Opin Immunol 2002 14 : 36 44.
113. Li H, Llera A, Mariuzza RA. Structure-function studies of T-cell receptor-superantigen interactions. Immunol Rev 1998 163 : 177 186.
114. Moza B, et al. Structural basis of T-cell specificity and activation by the bacterial superantigen TSST-1. EMBO J 2007 26 : 1187 1197.
115. Pumphrey N, Vuidepot A, Jakobsen B, Forsberg G, Walse B, Lindkvist-Petersson K. Cutting edge: evidence of direct TCR alpha-chain interaction with superantigen. J Immunol 2007 179 : 2700 2704.
116. Tranter HS. Foodborne staphylococcal illness. Lancet 1990 336 : 1044 1046.
117. Marrack P, Blackman M, Kushnir E, Kappler J. The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells. J Exp Med 1990 171 : 455 464.
118. Hovde CJ, et al. Investigation of the role of the disulphide bond in the activity and structure of staphylococcal enterotoxin C1. Mol Microbiol 1994 13 : 897 909.
119. Shupp JW, Jett M, Pontzer CH. Identification of a transcytosis epitope on staphylococcal enterotoxins. Infect Immun 2002 70 : 2178 2186.
120. Barrera CA, et al. Class II MHC-expressing myofibroblasts play a role in the immunopathogenesis associated with staphylococcal enterotoxins. Ann NY Acad Sci 2004 1029 : 313 318.
121. Pinchuk IV, et al. Monocyte chemoattractant protein-1 production by intestinal myofibroblasts in response to staphylococcal enterotoxin a: relevance to staphylococcal enterotoxigenic disease. J Immunol 2007 178 : 8097 8106.
122. Hu DL, et al. Staphylococcal enterotoxin induces emesis through increasing serotonin release in intestine and it is downregulated by cannabinoid receptor 1. Cell Microbiol 2007 9 : 2267 2277.
123. Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet 1978 2 : 1116 1118.
124. Kehrberg MW, et al. Risk factors for staphylococcal toxic-shock syndrome. Am J Epidemiol 1981 114 : 873 879.
125. Schuchat A, Broome CV. Toxic shock syndrome and tampons. Epidemiol Rev 1991 13 : 99 112.
126. Ferry T, et al. Comparative prevalence of superantigen genes in Staphylococcus aureus isolates causing sepsis with and without septic shock. Clin Infect Dis 2005 41 : 771 777.
127. Dauwalder O, et al. Comparative inflammatory properties of staphylococcal superantigenic enterotoxins SEA and SEG: implications for septic shock. J Leukoc Biol 2006 80 : 753 758.
128. Musser JM, et al. A single clone of Staphylococcus aureus causes the majority of cases of toxic shock syndrome. Proc Natl Acad Sci USA 1990 87 : 225 229.
129. Peterson ML, et al. The innate immune system is activated by stimulation of vaginal epithelial cells with Staphylococcus aureus and toxic shock syndrome toxin 1. Infect Immun 2005 73 : 2164 2174.
130. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001 55 : 77 104.
131. Ekelund K, Skinhoj P, Madsen J, Konradsen HB. Reemergence of emm1 and a changed superantigen profile for group A streptococci causing invasive infections: results from a nationwide study. J Clin Microbiol 2005 43 : 1789 1796.
132. Yang L, Thomas M, Woodhouse A, Martin D, Fraser JD, Proft T. Involvement of streptococcal mitogenic exotoxin Z in streptococcal toxic shock syndrome. J Clin Microbiol 2005 43 : 3570 3573.
133. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004 113 : 651 657.
134. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974 90 : 525 530.
135. Hoeger PH, Lenz W, Boutonnier A, Fournier JM. Staphylococcal skin colonization in children with atopic dermatitis: prevalence, persistence, and transmission of toxigenic and nontoxigenic strains. J Infect Dis 1992 165 : 1064 1068.
136. Michie CA, Davis T. Atopic dermatitis and staphylococcal superantigens. Lancet 1996 347 : 324.
137. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003 361 : 151 160.
138. Strickland I, Hauk PJ, Trumble AE, Picker LJ, Leung DY. Evidence for superantigen involvement in skin homing of T cells in atopic dermatitis. J Invest Dermatol 1999 112 : 249 253.
139. Savinko T, et al. Topical superantigen exposure induces epidermal accumulation of CD8+ T cells, a mixed Th1/Th2-type dermatitis and vigorous production of IgE antibodies in the murine model of atopic dermatitis. J Immunol 2005 175 : 8320 8326.
140. Shiomori T, Yoshida S, Miyamoto H, Makishima K. Relationship of nasal carriage of Staphylococcus aureus to pathogenesis of perennial allergic rhinitis. J Allergy Clin Immunol 2000 105 : 449 454.
141. Rossi RE, Monasterolo G. Prevalence of serum IgE antibodies to the Staphylococcus aureus enterotoxins (SAE, SEB, SEC, SED, TSST-1) in patients with persistent allergic rhinitis. Int Arch Allergy Immunol 2004 133 : 261 266.
142. Okano M, et al. Nasal exposure to Staphylococcal enterotoxin enhances the development of allergic rhinitis in mice. Clin Exp Allergy 2005 35 : 506 514.
143. Bachert C, van Zele T, Gevaert P, De Schrijver L, Van Cauwenberge P. Superantigens and nasal polyps. Curr Allergy Asthma Rep 2003 3 : 523 531.
144. Bachert C, Zhang N, Patou J, van Zele T, Gevaert P. Role of staphylococcal superantigens in upper airway disease. Curr Opin Allergy Clin Immunol 2008 8 : 34 38.
145. Stolz SJ, et al. Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin. J Infect Dis 1985 151 : 883 889.
146. Kansal R, et al. Structural and functional properties of antibodies to the superantigen TSST-1 and their relationship to menstrual toxic shock syndrome. J Clin Immunol 2007 27 : 327 338.
147. Norrby-Teglund A, Nepom GT, Kotb M. Differential presentation of group A streptococcal superantigens by HLA class II DQ and DR alleles. Eur J Immunol 2002 32 : 2570 2577.
148. Llewelyn M, et al. HLA class II polymorphisms determine responses to bacterial superantigens. J Immunol 2004 172 : 1719 1726.
149. Norrby-Teglund A, Low DE, Kotb M. Intravenous immunoglobulin therapy in superantigen-mediated toxic shock syndrome. In : Kotb M, Fraser JD, eds. Superantigens: Molecular Basis for their Role in Human Diseases. Washington : ASM Press, 2007 : 197 216.
150. Eriksson BK, Andersson J, Holm SE, Norgren M. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J Infect Dis 1999 180 : 410 418.
151. Basma H, et al. Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect Immun 1999 67 : 1871 1877.
152. Darenberg J, Soderquist B, Normark BH, Norrby-Teglund A. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 2004 38 : 836 842.
153. Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis 1998 26 : 631 638.
154. Schrage B, Duan G, Yang LP, Fraser JD, Proft T. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis 2006 43 : 743 746.
155. Arad G, Levy R, Hillman D, Kaempfer R. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med 2000 6 : 414 421.
156. Llewelyn M, Cohen J. Superantigen antagonist peptides. Crit Care 2001 5 : 53 55.
157. Rajagopalan G, Sen MM, David CS. In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonists. Infect Immun 2004 72 : 6733 6737.
158. Lehnert NM, et al. Structure-based design of a bispecific receptor mimic that inhibits T cell responses to a superantigen. Biochemistry 2001 40 : 4222 4228.
159. Hong-Geller E, Mollhoff M, Shiflett PR, Gupta G. Design of chimeric receptor mimics with different TCRVbeta isoforms. Type-specific inhibition of superantigen pathogenesis. J Biol Chem 2004 279 : 5676 5684.
160. Buonpane RA, et al. Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nat Med 2007 13 : 725 729.
161. Li Y, et al. Crystal structure of a superantigen bound to the high-affinity, zinc-dependent site on MHC class II. Immunity 2001 14 : 93 104.
162. Sundberg EJ, et al. Structures of two streptococcal superantigens bound to TCR beta chains reveal diversity in the architecture of T cell signaling complexes. Structure 2002 10 : 687 699.